Lauren Dugan, Aasim Naqvi, Ashley Ngor, Jayant Totlani, Tiffany Chang, Drew Hirsch, Salma Abdelmoteleb, Thomas Parrish, Piyush Nayyar, Kyla Truman, Michael Irwin, Robert N Pechnick, Itai Danovitch, Waguih W IsHak
{"title":"睡眠-觉醒障碍：已批准的精神科药物（2008 - 2024）和iii期药物的系统回顾。","authors":"Lauren Dugan, Aasim Naqvi, Ashley Ngor, Jayant Totlani, Tiffany Chang, Drew Hirsch, Salma Abdelmoteleb, Thomas Parrish, Piyush Nayyar, Kyla Truman, Michael Irwin, Robert N Pechnick, Itai Danovitch, Waguih W IsHak","doi":"10.1097/JCP.0000000000002049","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This systematic review examines the psychiatric medications approved by the Food and Drug Administration (FDA) for sleep-wake disorders within the past 17 years, from 2008 through 2024, to describe the mechanism of action, indications, evidence for efficacy, dosing, and adverse effects for each medication, as well as the medications that are in the pipeline for approval in phase 3.</p><p><strong>Methods: </strong>Studies published from January 1, 2008, until December 31, 2024, were identified from the PubMed database using the keywords \"sleep*\" AND \"disorder*\" OR \"psychopharm*\" AND \"medic*\" OR \"pharm*.\" An independent, focused analysis was conducted, and a consensus was reached on the studies to be included in this systematic review. Key findings were derived from the full text and tables of the selected studies.</p><p><strong>Results: </strong>From January 1, 2008, to December 31, 2024, the FDA approved 14 medications for sleep-wake disorders and three pipeline medications as of December 31, 2024, currently in phase 3 clinical trials.</p><p><strong>Conclusions: </strong>Through this comprehensive systematic review, stakeholders-including clinicians, researchers, policymakers, and patients-can gain insights into the current treatment landscape and anticipate future therapeutic innovations. This review serves as a resource for guiding treatment decisions and optimizing care for patients with sleep-wake disorders.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"493-505"},"PeriodicalIF":2.8000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Sleep-wake Disorders: Systematic Review of Approved Psychiatric Medications (2008 to 2024) and Pipeline Phase-3 Medications.\",\"authors\":\"Lauren Dugan, Aasim Naqvi, Ashley Ngor, Jayant Totlani, Tiffany Chang, Drew Hirsch, Salma Abdelmoteleb, Thomas Parrish, Piyush Nayyar, Kyla Truman, Michael Irwin, Robert N Pechnick, Itai Danovitch, Waguih W IsHak\",\"doi\":\"10.1097/JCP.0000000000002049\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>This systematic review examines the psychiatric medications approved by the Food and Drug Administration (FDA) for sleep-wake disorders within the past 17 years, from 2008 through 2024, to describe the mechanism of action, indications, evidence for efficacy, dosing, and adverse effects for each medication, as well as the medications that are in the pipeline for approval in phase 3.</p><p><strong>Methods: </strong>Studies published from January 1, 2008, until December 31, 2024, were identified from the PubMed database using the keywords \\\"sleep*\\\" AND \\\"disorder*\\\" OR \\\"psychopharm*\\\" AND \\\"medic*\\\" OR \\\"pharm*.\\\" An independent, focused analysis was conducted, and a consensus was reached on the studies to be included in this systematic review. Key findings were derived from the full text and tables of the selected studies.</p><p><strong>Results: </strong>From January 1, 2008, to December 31, 2024, the FDA approved 14 medications for sleep-wake disorders and three pipeline medications as of December 31, 2024, currently in phase 3 clinical trials.</p><p><strong>Conclusions: </strong>Through this comprehensive systematic review, stakeholders-including clinicians, researchers, policymakers, and patients-can gain insights into the current treatment landscape and anticipate future therapeutic innovations. This review serves as a resource for guiding treatment decisions and optimizing care for patients with sleep-wake disorders.</p>\",\"PeriodicalId\":15455,\"journal\":{\"name\":\"Journal of Clinical Psychopharmacology\",\"volume\":\" \",\"pages\":\"493-505\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical Psychopharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/JCP.0000000000002049\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/14 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/JCP.0000000000002049","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Sleep-wake Disorders: Systematic Review of Approved Psychiatric Medications (2008 to 2024) and Pipeline Phase-3 Medications.
Purpose: This systematic review examines the psychiatric medications approved by the Food and Drug Administration (FDA) for sleep-wake disorders within the past 17 years, from 2008 through 2024, to describe the mechanism of action, indications, evidence for efficacy, dosing, and adverse effects for each medication, as well as the medications that are in the pipeline for approval in phase 3.
Methods: Studies published from January 1, 2008, until December 31, 2024, were identified from the PubMed database using the keywords "sleep*" AND "disorder*" OR "psychopharm*" AND "medic*" OR "pharm*." An independent, focused analysis was conducted, and a consensus was reached on the studies to be included in this systematic review. Key findings were derived from the full text and tables of the selected studies.
Results: From January 1, 2008, to December 31, 2024, the FDA approved 14 medications for sleep-wake disorders and three pipeline medications as of December 31, 2024, currently in phase 3 clinical trials.
Conclusions: Through this comprehensive systematic review, stakeholders-including clinicians, researchers, policymakers, and patients-can gain insights into the current treatment landscape and anticipate future therapeutic innovations. This review serves as a resource for guiding treatment decisions and optimizing care for patients with sleep-wake disorders.
期刊介绍：
Journal of Clinical Psychopharmacology, a leading publication in psychopharmacology, offers a wide range of articles reporting on clinical trials and studies, side effects, drug interactions, overdose management, pharmacogenetics, pharmacokinetics, and psychiatric effects of non-psychiatric drugs. The journal keeps clinician-scientists and trainees up-to-date on the latest clinical developments in psychopharmacologic agents, presenting the extensive coverage needed to keep up with every development in this fast-growing field.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
